Biotechnology

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals receives EMA approval for the third phase Serenta clinical trial for Familial Adenomatous Polyposis

Biodexa Pharmaceuticals released FY2025 Semi-Annual earnings on September 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -20.0729 (forecast USD --)

Biodexa Pharmaceuticals released FY2025 Q1 earnings on September 12 (EST) with actual revenue of USD 0 and EPS of USD -9.7496

Biodexa Pharmaceuticals released FY2025 Q2 earnings on September 12 (EST), actual revenue USD 0, actual EPS USD -10.3233

Biodexa Submits Phase 3 Clinical Trial Application for FAP to EMA

Biodexa Launches Tolimidone Phase 2a Clinical Trial

Biodexa Enrolls First Patient in Phase 2 Tolimidone Study for Type 1 Diabetes

Biodexa Pharmaceuticals and Emtora Biosciences Receive Additional CPRIT Funding

Biodexa Pharmaceuticals Obtains Orphan Drug Designation and Launches FAP Phase III Clinical Trial

Biodexa Pharmaceuticals to Hold Shareholder Meeting to Vote on Three Strategic Resolutions

Biodexa Pharmaceuticals released FY2024 Q4 earnings on April 11, 2025 (EST) with actual revenue of USD 0 and EPS of USD -22.9242

Biodexa Pharmaceuticals released FY2024 9 Months Earnings on April 11 (EST), with actual revenue of USD 0 and EPS of USD -15.1788

Biodexa Pharmaceuticals released FY2024 annual earnings on April 11, 2025 (EST), with actual revenue of USD 0 and EPS of USD -14.799

Biodexa Pharmaceuticals released FY2024 Q3 earnings on April 11 (EST) with actual revenue of USD 0 and EPS of USD -24.4418

Biodexa Reports Positive Progress in Discussions with FDA on eRapa for FAP

Biodexa Pharmaceuticals released FY2024 Q2 earnings on September 26 (EST) with actual revenue of USD 0 and EPS of USD -63.7295

Biodexa Pharmaceuticals released FY2024 Semi-Annual earnings on September 26 (EST), actual revenue USD 0 (forecast USD 16.43K), actual EPS USD -127.3465

Biodexa Pharmaceuticals released FY2024 Q1 earnings on September 26 (EST) with actual revenue of USD 0 and EPS of USD -63.6169

Biodexa Pharmaceuticals released FY2023 Q4 earnings on April 19 (EST), actual revenue USD 52.9 K, actual EPS USD 0

Biodexa Pharmaceuticals released FY2023 9 Months Earnings on April 19 (EST), actual revenue USD 423.79K, actual EPS USD 0

Treasure Gbl

SMX Security Matters

Gulf Resources

Wheeler Real Estate

DigitalBridge

Irobot

Dreamland

Lichen

Toro

Alumis

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap